Schwaner, Ingo http://orcid.org/0000-0001-8865-7282
Kuhn, Thomas
Losem, Christoph
Wolff, Thomas
Otremba, Burkhard
Zaiss, Matthias
Hülsenbeck, Johannes
Famulla, Kirsten
Nösslinger, Thomas
Rossi, Davide
Funding for this research was provided by:
AbbVie Deutschland (AbbVie Deutschland)
Article History
Received: 30 September 2023
Accepted: 19 January 2024
First Online: 29 February 2024
Declarations
:
: The study was approved by the ethics commission of Berlin.
: Prior written consent was obtained for all patients enrolled in the study.
: BO has received honoraria for participation in advisory boards from AbbVie. IS has received honoraria from AbbVie, Amgen, AstraZeneca, BeiGene, Janssen, Roche, Servier, CL received consulting fees from AbbVie, Amgen. TW received honoraria or research funding Novartis, Celgene, Roche, Bayer, BMS and AbbVie, DR has received honoraria or research grants from AbbVie, AstraZeneca, Gilead, Janssen, Verastem, Roche, Cellestia, TK, JH and KF are employees of AbbVie and may own AbbVie stock.